Acute promyelocytic leukemia. Management of the coagulopathy during daunorubicin-prednisone remission induction: Management of the Coagulopathy During Daunorubicin-Prednisone Remission Induction

A. J. Collins; C. D. Bloomfield; B. A. Peterson; R. W. McKenna; J. R. Edson

doi:10.1001/archinte.1978.03630360059024

Acute promyelocytic leukemia. Management of the coagulopathy during daunorubicin-prednisone remission induction: Management of the Coagulopathy During Daunorubicin-Prednisone Remission Induction

A. J. Collins, C. D. Bloomfield, B. A. Peterson, R. W. McKenna, J. R. Edson

Research output: Contribution to journal › Article › peer-review

53 Scopus citations

Abstract

Seven adults with acute promyelocytic leukemia (APL) and disseminated intravascular coagulation were treated for remission induction with daunorubicin hydrochloride and prednisone. In all patients the coagulopathy was managed with continuous-infusion heparin sodium and vigorous transfusion with platelets, cryoprecipitate, and fresh frozen plasma. Five patients survived induction; they all achieved complete remission (CR). Median duration of CR was 27+ months; two patients presently survive in their initial CR at 28 and 48 months. Recognition of APL as a distinct type of acute leukemia and prompt initiation of treatment aimed at rapid cytoreduction and control of the coagulopathy has resulted in a prolonged disease-free survival for the majority of patients.

Original language	English (US)
Pages (from-to)	1677-1680
Number of pages	4
Journal	Archives of Internal Medicine
Volume	138
Issue number	11
DOIs	https://doi.org/10.1001/archinte.1978.03630360059024
State	Published - 1978

Bibliographical note

Copyright:
Copyright 2015 Elsevier B.V., All rights reserved.

PubMed: MeSH publication types

Journal Article
Research Support, U.S. Gov't, P.H.S.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1001/archinte.1978.03630360059024

OpenUrl availability

Full text

Cite this

Collins, A. J., Bloomfield, C. D., Peterson, B. A., McKenna, R. W., & Edson, J. R. (1978). Acute promyelocytic leukemia. Management of the coagulopathy during daunorubicin-prednisone remission induction: Management of the Coagulopathy During Daunorubicin-Prednisone Remission Induction. Archives of Internal Medicine, 138(11), 1677-1680. https://doi.org/10.1001/archinte.1978.03630360059024

Acute promyelocytic leukemia. Management of the coagulopathy during daunorubicin-prednisone remission induction: Management of the Coagulopathy During Daunorubicin-Prednisone Remission Induction. / Collins, A. J.; Bloomfield, C. D.; Peterson, B. A. et al.
In: Archives of Internal Medicine, Vol. 138, No. 11, 1978, p. 1677-1680.

Research output: Contribution to journal › Article › peer-review

Collins, AJ, Bloomfield, CD, Peterson, BA, McKenna, RW & Edson, JR 1978, 'Acute promyelocytic leukemia. Management of the coagulopathy during daunorubicin-prednisone remission induction: Management of the Coagulopathy During Daunorubicin-Prednisone Remission Induction', Archives of Internal Medicine, vol. 138, no. 11, pp. 1677-1680. https://doi.org/10.1001/archinte.1978.03630360059024

@article{a7c8b074018a431994013393668a8aa6,

title = "Acute promyelocytic leukemia. Management of the coagulopathy during daunorubicin-prednisone remission induction: Management of the Coagulopathy During Daunorubicin-Prednisone Remission Induction",

abstract = "Seven adults with acute promyelocytic leukemia (APL) and disseminated intravascular coagulation were treated for remission induction with daunorubicin hydrochloride and prednisone. In all patients the coagulopathy was managed with continuous-infusion heparin sodium and vigorous transfusion with platelets, cryoprecipitate, and fresh frozen plasma. Five patients survived induction; they all achieved complete remission (CR). Median duration of CR was 27+ months; two patients presently survive in their initial CR at 28 and 48 months. Recognition of APL as a distinct type of acute leukemia and prompt initiation of treatment aimed at rapid cytoreduction and control of the coagulopathy has resulted in a prolonged disease-free survival for the majority of patients.",

author = "Collins, {A. J.} and Bloomfield, {C. D.} and Peterson, {B. A.} and McKenna, {R. W.} and Edson, {J. R.}",

year = "1978",

doi = "10.1001/archinte.1978.03630360059024",

language = "English (US)",

volume = "138",

pages = "1677--1680",

journal = "Archives of Internal Medicine",

issn = "0003-9926",

publisher = "American Medical Association",

number = "11",

}

TY - JOUR

T1 - Acute promyelocytic leukemia. Management of the coagulopathy during daunorubicin-prednisone remission induction

T2 - Management of the Coagulopathy During Daunorubicin-Prednisone Remission Induction

AU - Collins, A. J.

AU - Bloomfield, C. D.

AU - Peterson, B. A.

AU - McKenna, R. W.

AU - Edson, J. R.

PY - 1978

Y1 - 1978

N2 - Seven adults with acute promyelocytic leukemia (APL) and disseminated intravascular coagulation were treated for remission induction with daunorubicin hydrochloride and prednisone. In all patients the coagulopathy was managed with continuous-infusion heparin sodium and vigorous transfusion with platelets, cryoprecipitate, and fresh frozen plasma. Five patients survived induction; they all achieved complete remission (CR). Median duration of CR was 27+ months; two patients presently survive in their initial CR at 28 and 48 months. Recognition of APL as a distinct type of acute leukemia and prompt initiation of treatment aimed at rapid cytoreduction and control of the coagulopathy has resulted in a prolonged disease-free survival for the majority of patients.

AB - Seven adults with acute promyelocytic leukemia (APL) and disseminated intravascular coagulation were treated for remission induction with daunorubicin hydrochloride and prednisone. In all patients the coagulopathy was managed with continuous-infusion heparin sodium and vigorous transfusion with platelets, cryoprecipitate, and fresh frozen plasma. Five patients survived induction; they all achieved complete remission (CR). Median duration of CR was 27+ months; two patients presently survive in their initial CR at 28 and 48 months. Recognition of APL as a distinct type of acute leukemia and prompt initiation of treatment aimed at rapid cytoreduction and control of the coagulopathy has resulted in a prolonged disease-free survival for the majority of patients.

UR - http://www.scopus.com/inward/record.url?scp=0018047252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018047252&partnerID=8YFLogxK

U2 - 10.1001/archinte.1978.03630360059024

DO - 10.1001/archinte.1978.03630360059024

M3 - Article

C2 - 281191

AN - SCOPUS:84942733724

SN - 0003-9926

VL - 138

SP - 1677

EP - 1680

JO - Archives of Internal Medicine

JF - Archives of Internal Medicine

IS - 11

ER -

Acute promyelocytic leukemia. Management of the coagulopathy during daunorubicin-prednisone remission induction: Management of the Coagulopathy During Daunorubicin-Prednisone Remission Induction

Abstract

Bibliographical note

PubMed: MeSH publication types

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this